Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia

Cardiovascular Therapeutics

Volumn 32, Issue 4, 2014, Pages 139-146

  Kei, Anastazia ^a   Tellis, Constantinos ^b   Liberopoulos, Evangelos ^a   Tselepis, Alexandros ^b   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

F2 Isoprostanes; Fenofibrate; Mixed dyslipidemia; Nicotinic acid laropiprant; Oxidative stress; Oxidized LDL; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ATORVASTATIN; BILIRUBIN; CREATININE; FENOFIBRATE; ISOPROSTANE DERIVATIVE; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; NICOTINIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; ROSUVASTATIN; SIMVASTATIN; URIC ACID; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTILIPEMIC AGENT; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MK-0524; OXIDIZED LOW DENSITY LIPOPROTEIN; PROSTAGLANDIN F2 ALPHA; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY TEMPERATURE DISORDER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPIGASTRIC PAIN; FEMALE; FLUSHING; FOLLOW UP; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED DYSLIPIDEMIA; MONOTHERAPY; OPEN STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; SINGLE BLIND PROCEDURE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; DYSLIPIDEMIAS; GREECE; TIME; TREATMENT OUTCOME;

AGED; APOLIPOPROTEIN B-100; BILIRUBIN; BIOLOGICAL MARKERS; DINOPROST; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FLUOROBENZENES; GREECE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NIACIN; OXIDATIVE STRESS; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84904012649     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12072     Document Type: Article

References (51)

1. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
3. Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008;13:157-174.
4. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.
5. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV6-IV19.
6. Durrington P. Dyslipidaemia. Lancet 2003;362:717-731.
7. Kei A, Liberopoulos EN, Mikhailidis DP, Elisaf M. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. Int J Clin Pract 2013;67:412-419.
8. Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidaemia: a randomized pilot trial. Eur J Clin Invest 2013;43:698-707.
9. Kei A, Liberopoulos E, Tellis C, Elisaf M, Tselepis A. Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions. Lipids 2013;48:957-965.
10. Hamoud S, Kaplan M, Meilin E, Hassan A, Torgovicky R, Cohen R, Hayek T. Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol. Am J Med Sci 2013;345:195-199.
11. Florentin M, Liberopoulos EN, Kei A, Mikhailidis DP, Elisaf MS. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011;9:385-400.
12. Walker AE, Kaplon RE, Lucking SM, Russell-Nowlan MJ, Eckel RH, Seals DR. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension 2012;60:1517-1523.
13. Agouridis AP, Tsimihodimos V, Filippatos TD, et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother 2011;12:2605-2611.
14. Dong Y, Steffen BT, Cao J, et al. Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis 2011;214:422-425.
15. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, Elisaf M. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther 2006;11:256-261.
16. Holvoet P, Donck J, Landeloos M, et al. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996;76:663-669.
17. Tsouli SG, Kiortsis DN, Lourida ES, et al. Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. J Lipid Res 2006;47:2208-2214.
18. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-513.
19. Griffiths HR, Moller L, Bartosz G, et al. Biomarkers. Mol Aspects Med 2002;23:101-208.
20. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-9387.
21. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-286.
22. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-161.
23. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002;22:1162-1167.
24. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-848.
25. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57.
26. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
27. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006;61:262-274.
28. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001;110:103-110.
29. Tkac I, Molcanyiova A, Javorsky M, Kozarova M. Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity. Pharmacol Res 2006;53:261-264.
30. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 2008;196:122-128.
31. Azhar S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol 2010;6:657-691.
32. Niu N, Yu YH, Wang Y, Wang LJ, Li Q, Guo LM. Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats. Mol Biol Rep 2009;36:1275-1281.
33. Kaplon RE, Gano LB, Seals DR. Vascular endothelial function and oxidative stress are related to dietary niacin intake among healthy middle-aged and older adults. J Appl Physiol (1985) 2013;116:156-163.
34. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001;104:2498-2502.
35. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001;104:2376-2383.
36. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990;1044:275-283.
37. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-2891.
38. van Tits LJ, van Himbergen TM, Lemmers HL, de Graaf J, Stalenhoef AF. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2006;185:307-312.
39. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004;29:30369-30374.
40. Kei A, Liberopoulos EN, Elisaf M. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 2013;4:365-371.
41. Sautin YY, Johnson RJ. Uric acid: the oxidant-antioxidant paradox. Nucleo Nucleot Nucl Acids 2008;27:608-619.
42. Jansen T, Daiber A. Direct antioxidant properties of bilirubin and biliverdin. Is there a role for biliverdin reductase? Front Pharmacol 2012;3:30.
43. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004;15:251-258.
44. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
45. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565.
46. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
47. Group, H.T.C. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-1291.
48. Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
49. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Diabetes Care 2011;34(Suppl. 2):S107-S108.
50. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011;365:2078-2087.
51. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.